HeartBeat.bio, based in Vienna, Austria, is a recently founded drug discovery company focusing on the development of a high-throughput 3D screening platform for heart failure and cardiomyopathy. The company’s core technology is based on the world-wide first, self-organizing cardiac organoids (Cardioids) which resemble the human physiology of a human heart chamber in a way that allows for the cost-efficient and large scale in-vitro analysis of crucial clinical parameters associated with various cardiac diseases. The Cardioid-based screening platform has the potential to radically change the current cardiovascular drug discovery paradigm. The company was founded on Jan 1, 2021.